SAN DIEGO, Nov. 02, 2026 (GLOBE NEWSWIRE) — iBio, I c. (NASDAQ: IBIO), a cli ical-stage biotech ology compa y developi g lo g-acti g a tibody the apeutics fo obesity, ca diometabolic a d ca diopulmo a y diseases, today a ou ced that Ma ti B e e , DVM, Ph.D., Chief Executive Office a d Chief Scie tific Office , a d Felipe Du a , Chief Fi a cial Office , will pa ticipate i the followi g i vesto co fe e ces i Novembe a d Decembe 2026.
Gugge heim Healthca e I ovatio 2026 Co fe e ce Whe : Novembe 9 – 11 Fo mat: Fi eside chatDate & Time: Novembe 10, 2026: 9:00 a.m. ET Locatio : Bosto
A livest eam of the eve t ca be accessed he e.
Jeffe ies Global Healthca e Co fe e ce Whe : Novembe 16 – 19 Fo mat: 1:1 Meeti gsLocatio : The Waldo f Hilto , Lo do
Pipe Sa dle 38th A ual Healthca e Co fe e ce Dates: Decembe 1 – 3 Fo mat: Fi eside ChatDate & Time: Decembe 1, 9:30-9:55 a.m. ETP ese te s: Ma ti B e e , Felipe Du a Locatio : Lotte New Yo k Palace, New Yo k City
A livest eam of the eve t ca be accessed f om the eve ts page of the iBio website.
D . B e e a d M . Du a will be available fo o e-o -o e meeti gs du i g each co fe e ce. A li k to access each of the eplays a d p ese tatio s will be available o the I vesto sectio of the iBio website fo 90 days afte the eve t.
About iBio, I c.
iBio (Nasdaq: IBIO) is a cli ical-stage biotech ology developi g lo g-acti g a tibody the apeutics fo obesity, ca diometabolic a d ca diopulmo a y diseases, ca ce , a d othe ha d-to-t eat diseases. Combi i g adva ced a tibody e gi ee i g with AI-d ive discove y, iBio is adva ci g a diffe e tiated pipeli e desig ed to delive sustai ed the apeutic effects a d add ess sig ifica t u met medical eeds. iBio’s missio is to t a sfo m d ug discove y, accele ate developme t timeli es, a d u lock ew possibilities i p ecisio medici e.
Fo mo e i fo matio , visit www.ibioi c.com o follow us o Li kedI .
I vesto Co tactMatt Beckast pa t e smatthew.beck@ast pa t e s.com(917) 415-1750
Media Co tactJaso B aco, Ph.D.Vale ce Commu icatio sjaso @vale cecomms.com
![]()
